[Therapeutic considerations on secondary osteoporosis caused by diabetes mellitus].
Diagnosis and treatment of osteoporosis are evolving from BMD (bone mineral density) dependent manner to bone quality conscious manner. However, clinical methods to evaluate bone quality of diabetic patients have not been established yet. Therefore, many potentially osteoporotic patients with diabetes are not recognized as high fracture risk patients under the current therapeutic guideline of osteoporosis. On the other hand, some drugs for osteoporosis affect pathophysiology of diabetes. In the future, it is possible that drugs for osteoporosis are chosen according to the diabetic state of each patient.
Azuma
Kotaro
K
Department of Geriatric Medicine, University of Tokyo Hospital.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D048909:Diabetes Complications; D004164:Diphosphonates / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use; D014812:Vitamin K / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D014812:Vitamin K; D014807:Vitamin D; D020849:Raloxifene Hydrochloride